Evidence map›Paper›PMID 2959623›Full record

Trial reportInfection and immunity1987

Oral immunization of humans with Streptococcus sobrinus glucosyltransferase.

D J Smith, M A Taubman

Open access · bronzeAbstract readClinical TrialControlled Clinical Trial
In one paragraph

Trial report in Infection and immunity, 1987. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 74 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Human T-cell responses to the glucosyltransferases of Streptococcus mutans.Clinical and diagnostic laboratory immunology · 2001
    Article
  13. Oral microbial ecology and the role of salivary immunoglobulin A.Microbiology and molecular biology reviews : MMBR · 1998
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

D J SmithDepartment of Immunology, Forsyth Dental Center, Boston, Massachusetts 02115.
M A Taubman
Novant Health Forsyth Medical Center · US

Funding

CHILDHOOD VACCINES AND DENTAL CARIES IMMUNITYR37DE006153 · NIDCR · FORSYTH INSTITUTE · PI SMITH, DANIEL JAMES · 1998 to 2007
$3.9M
SYNTHETIC PEPTIDE VACCINES FOR DENTAL CARIESR01DE004733 · NIDCR · FORSYTH INSTITUTE · PI TAUBMAN, MARTIN A · 1985 to 2005
$3.0M
Passive Immunotherapy for Pediatric Mutans Streptococcal InfectionsR56DE004733 · NIDCR · ADA FORSYTH INSTITUTE, INC. · PI TAUBMAN, MARTIN A · 2007 to 2009
$2.1M
CHILDHOOD VACCINES AND DENTAL CARIES IMMUNITYR01DE006153 · NIDCR · FORSYTH INSTITUTE · PI SMITH, DANIEL J. · 1985 to 1998
–
NIDCR NIH HHS DE-04733NIDCR NIH HHS DE-06153
6 · The paper itself

Abstract

The effect of oral administration of glucosyltransferase (GTF) from Streptococcus sobrinus 6715 on levels of immunoglobulin A (IgA) antibody to GTF in parotid saliva and on the number of indigenous Streptococcus mutans in the whole saliva was studied in young adult males. GTF combined with aluminum phosphate (AP) was administered in capsules to 14 subjects, while sodium phosphate buffer combined with AP was administered in the same way to 11 control subjects. Thirteen administrations were given during the first immunization regimen, and five administrations, approximately 3 months later, constituted the second immunization regimen. All subjects were given professional dental prophylaxis immediately prior to each immunization. Each subject served as his own control by using antibody and bacterial data collected prior to antigen administration for comparison. After the first immunization regimen, the GTF vaccine group exhibited a significantly higher distribution (P less than 0.05) of normalized parotid saliva IgA antibody elevations than observed in the placebo group. Between the first and second immunization regimens a significant increase (P less than 0.05) in parotid salivary anti-GTF activity also occurred in the GTF vaccine but not the placebo group. No significant differences between these two groups were observed on any occasion when serum IgG or IgA antibody to GTF was analyzed. Comparison of the group mean log ratios (post- to prevaccine administration) of S. mutans to total streptococci in whole saliva revealed that the GTF vaccine group values were always lower than those of the placebo group. These differences reached significance (P less than 0.01) on three of the last four sampling occasions (days 21, 35, and 42) following initiation of the first immunization regimen. The mean log ratios of the GTF vaccine group were also lower than those of the placebo group after the second immunization regimen but did not reach significance. These data indicate that oral administration of GTF from the mutans streptococci has the potential to elicit a salivary IgA antibody response when combined with an aluminum-based adjuvant and that this response can interfere with the reaccumulation of indigenous S. mutans following dental prophylaxis.

Indexed as

Administration, OralAntibodies, BacterialBacterial VaccinesGlucosyltransferasesHumansImmunizationImmunoglobulin A, SecretoryImmunoglobulin GSalivaStreptococcusTime FactorsAntibodies, BacterialBacterial VaccinesGlucosyltransferasesImmunoglobulin A, SecretoryImmunoglobulin G

Identifiers

PMID2959623
PMCPMC259942
OpenAlexW1930106629

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.